Eli Lilly

Academic-industry collaboration seeks new drugs, treatments for autism

Monday, March 19, 2012 02:41 PM

An international consortium of scientists led by Roche, King's College London and Autism Speaks is collaborating on one of the largest ever academic-industry research projects, to find new methods for the development of drugs for autism spectrum disorder (ASD), which affects 1% of children worldwide.

More... »

Hovione appoints Minchom vice president

Wednesday, March 14, 2012 09:14 AM

Dr. Colin Minchom has been appointed as vice president of Hovione’s particle design business unit. He will be based in East Windsor, N.J., and report to Guy Villax, CEO of Hovione.

More... »

Dendreon appoints three to executive team

Wednesday, March 14, 2012 09:10 AM

Seattle, Wash.-based Dendreon has appointed three new members to its executive team:

More... »

Lilly introduces global 'Innovation Starts Here' initiative

Thursday, March 1, 2012 06:02 AM

Eli Lilly has launched a global Innovation Starts Here initiative, which supports Lilly's commitment to speeding the delivery of innovative new medicines to patients around the world.

More... »

Lilly to invest $442 million in new biopharma facility in Ireland

Monday, February 27, 2012 03:18 PM

Eli Lilly is investing $442 million in a brand-new biopharmaceutical commercialization and manufacturing facility at its Kinsale campus in Cork, Ireland, according to Richard Bruton TD, minister for jobs, enterprise and innovation.

More... »

Sangart appoints three to leadership team

Friday, February 17, 2012 12:43 PM

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

More... »

Dendreon announces CEO and chairman succession plan

Wednesday, February 1, 2012 03:41 PM

Dendreon’s board of directors has elected John H. Johnson president and CEO, succeeding Mitchell H. Gold, M.D., who has served as both for nearly a decade.

More... »

ImmunoGen collaborates with Lilly

Tuesday, December 20, 2011 11:02 AM

ImmunoGen has entered into a collaboration agreement with Eli Lilly. Under this agreement, Lilly will pay an upfront fee of $20 million for rights to take a limited number of exclusive licenses to use ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology with Lilly monoclonal antibodies to develop novel antibody-drug conjugate (ADC) anticancer therapeutics.

More... »

The CenterWatch Monthly, December 2011

Thursday, December 1, 2011 09:46 AM

Canada scrambles to reboot sagging clinical trials market

More... »

UCB inks strategic partnerships with Parexel, PRA

Monday, November 28, 2011 08:00 AM

The sponsor-CRO strategic partnerships just keep coming. 

More... »